<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Pretreatment HIV drug resistance among HIV-infected individuals initiating ART in 2017 in China, by region</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="2"/>
    <th rowspan="2">Number</th>
    <th rowspan="2">Number of PDR</th>
    <th rowspan="2">Prevalence (%)</th>
    <th colspan="3">Prevalence (%)</th>
   </tr>
   <tr>
    <th>NNRTIs</th>
    <th>NRTIs</th>
    <th>PIs</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Total</td>
    <td>1711</td>
    <td>117</td>
    <td>6.8</td>
    <td>4.6(79/1711)</td>
    <td>2.2 (38/1711)</td>
    <td>0.6 (10/1711)</td>
   </tr>
   <tr>
    <td>High prevalence regions</td>
    <td>1102</td>
    <td>90</td>
    <td>8.2</td>
    <td>5.5(61/1102)</td>
    <td>2.8 (31/1102)</td>
    <td>0.6 (7//1102)</td>
   </tr>
   <tr>
    <td>Dehong, Yunnan</td>
    <td>150</td>
    <td>14</td>
    <td>9.3</td>
    <td>8.7(13/150)</td>
    <td>0.7 (1/150)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Lincang, Yunnan</td>
    <td>158</td>
    <td>14</td>
    <td>8.9</td>
    <td>5.7(9/158)</td>
    <td>3.8 (6/158)</td>
    <td>1.3 (2/158)</td>
   </tr>
   <tr>
    <td>Liuzhou, Guangxi</td>
    <td>207</td>
    <td>11</td>
    <td>5.3</td>
    <td>2.9(6/207)</td>
    <td>1.9 (4/207)</td>
    <td>0.5 (1/207)</td>
   </tr>
   <tr>
    <td>Nanning, Guangxi</td>
    <td>104</td>
    <td>7</td>
    <td>6.7</td>
    <td>3.9(4/104)</td>
    <td>3.8 (4/104)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Liangshan, Sichuan</td>
    <td>279</td>
    <td>34</td>
    <td>12.2</td>
    <td>9.0(25/279)</td>
    <td>3.9 (11/279)</td>
    <td>1.1 (3/279)</td>
   </tr>
   <tr>
    <td>Neijiang, Sichuan</td>
    <td>105</td>
    <td>5</td>
    <td>4.8</td>
    <td>1.0(1/105)</td>
    <td>2.9 (3/105)</td>
    <td>1.0 (1/105)</td>
   </tr>
   <tr>
    <td>Shenzhen, Guangdong</td>
    <td>99</td>
    <td>5</td>
    <td>5.1</td>
    <td>3.0(3/99)</td>
    <td>2.0 (2/99)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Moderate prevalence regions</td>
    <td>609</td>
    <td>27</td>
    <td>4.4</td>
    <td>3.0(18/609)</td>
    <td>1.1 (7/609)</td>
    <td>0.5 (3/609)</td>
   </tr>
   <tr>
    <td>Chongqing</td>
    <td>85</td>
    <td>5</td>
    <td>5.9</td>
    <td>2.4(2/85)</td>
    <td>1.2 (1/85)</td>
    <td>2.4 (2/85)</td>
   </tr>
   <tr>
    <td>Guizhou</td>
    <td>112</td>
    <td>5</td>
    <td>4.5</td>
    <td>1.8(2/112)</td>
    <td>1.8 (2/112)</td>
    <td>0.9 (1/112)</td>
   </tr>
   <tr>
    <td>Hunan</td>
    <td>97</td>
    <td>2</td>
    <td>2.1</td>
    <td>2.1(2/97)</td>
    <td>1.0 (1/97)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Beijing</td>
    <td>111</td>
    <td>4</td>
    <td>3.6</td>
    <td>2.7(3/111)</td>
    <td>0.9 (1/111)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Jiangsu</td>
    <td>105</td>
    <td>5</td>
    <td>4.8</td>
    <td>4.8(5/105)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Shandong</td>
    <td>99</td>
    <td>6</td>
    <td>6.1</td>
    <td>4.0(4/99)</td>
    <td>2.0 (2/99)</td>
    <td>0</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>PDR</italic> Pretreatment drug resistance, 
   <italic>NNRTI</italic> Non-nucleoside reverse transcriptase inhibitor, 
   <italic>NRTI</italic> nucleoside reverse transcriptase inhibitor, 
   <italic>PI</italic> Protease inhibitor.
  </p>
 </table-wrap-foot>
</table-wrap>
